Though programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitors have revolutionized cancer treatment, predicting their therapeutic efficacy largely depends on biomarkers obtained through invasive procedures, which present challenges, particularly for continuous sampling. The gene discussed is CD274; the disease is cancer.